Skip to main content

Table 3 Statistics for experiment 2 to determine the effects of estrous phase (proestrus vs. non-proestrus phases)

From: Sex differences in a mouse model of multiple sclerosis: neuropathic pain behavior in females but not males and protection from neurological deficits during proestrus

  Two-way RM ANOVA (treatment × estrous)
BL Day 7 Day 13 Day 21 Day 29 Day 35 Day 42
Clinical scores, Figure 5A        
 Treatment F1,28 = 0.2, P = 0.6 F1, 27 = 2.0, P = 0.16 F1,30 = 1.09, P = 0.3 F1,30 = 10.3, P < 0.05 F1,31 = 8.5, P < 0.01 F1,31 = 0.5, P = 0.4 F1,31 = 2.2, P = 0.1
 Estrous F1,28 = 0.2, P = 0.6 F1, 27 = 0.5, P = 0.4 F1,30 = 0.2, P = 0.5 F1,30 = 0.6, P = 0.4 F1,31 = 1.1, P = 0.2 F1,31 = 3.0, P = 0.09 F1,31 = 2.8, P = 0.053
 Treatment × estrous F1,28 = 0.2, P = 0.6 F1, 27 = 0.001, P = 0.9 F1,30 = 1.09, P = 0.3 F1,30 = 0.6, P = 0.4 F1,31 = 0.2, P = 0.9 F1,31 = 3.7, P = 0.6 F1,31 = 3.7, P < 0.05
Grip strength, Figure 5C        
 Treatment F1,28 = 0.3, P = 0.5 F1. 27 = 2.7, P = 0.1 F1,30 = 0.09, P = 0.7 F1,30 = 11.0, P < 0.05 F1,31 = 19.8, P < 0.001 F1,31 = 5.8, P < 0.05 F1,31 = 6.4, P < 0.05
 Estrous F1,28 = 0.04, P = 0.8 F1, 27 = 0.7, P = 0.3 F1,30 = 0.6, P = 0.4 F1,30 = 0.002, P = 0.9 F1,31 = 0.05, P = 0.8 F1,31 = 0.1, P = 0.7 F1,31 = 0.1, P = 0.7
 Treatment × estrous F1,28 = 0.3, P = 0.5 F1, 27 = 0.06, P = 0.8 F1,30 = 2.1, P = 0.15 F1,30 = 0.5, P = 0.4 F1,31 = 0.02, P = 0.8 F1,31 = 0.009, P = 0.9 F1,31 = 0.02, P = 0.8
Mechanical thresholds, Figure 5E        
 Treatment F1,28 = 0.08, P = 0.7 F1, 27 = 4.2, P < 0.05 F1,30 = 0.7, P = 0.3 F1,30 = 7.4, P < 0.05 F1,31 = 25.9, P < 0.001 F1,31 = 2.0, P = 0.16 F1,31 = 3.5, P = 0.07
 Estrous F1,28 = 0.9, P = 0.3 F1, 27 = 0.4, P = 0.4 F1,30 = 2.3, P = 0.13 F1,30 = 0.09, P = 0.7 F1,31 = 5.2, P < 0.05 F1,31 = 3.1, P = 0.08 F1,31 = 0.2, P = 0.6
 Treatment × estrous F1,28 = 0.001, P = 0.9 F1, 27 = 0.09, P = 0.7 F1,30 = 0.1, P = 0.7 F1,30 = 1.5, P = 0.2 F1,31 = 8.7, P < 0.01 F1,31 = 2.1, P = 0.14 F1,31 = 2.6, P = 0.11
Acetone withdrawal, Figure 5G        
 Treatment F1,28 = 0.1, P = 0.7 F1,27 = 1.9, P =0.17 F1,30 = 4.2, P < 0.05 F1,30 = 4.2, P < 0.05 F1,31 = 5.2, P < 0.05 F1,31 = 1.0, P = 0.3 F1,31 = 7.2, P < 0.05
 Estrous F1,28 = 0.01, P = 0.9 F1,27 = 0.000, P = 0.9 F1,30 = 0.01, P = 0.9 F1,30 = 0.02, P = 0.6 F1,31 = 0.001, P = 0.9 F1,31 = 0.8, P = 0.7 F1,31 = 0.09, P = 0.7
 Treatment × estrous F1,28 = 0.9, P = 0.3 F1,27 = 0.06, P = 0.7 F1,30 = 0.001, P = 0.9 F1,30 = 1.2, P = 0.2 F1,31 = 0.2, P = 0.6 F1,31 = 3.7, P = 0.06 F1,31 = 6.3, P < 0.05
AUC Clinical scores:   Grip strength:   Mechanical thresholds:   Acetone withdrawal:
one-way ANOVA:   one-way ANOVA:   one-way ANOVA:   one-way ANOVA:
F3,44 = 8.8, P < 0.001   F3,44 = 5.3, P < 0.01   F3,44 = 5.8, P < 0.01   F3,44 = 2.8, P < 0.05
  (Figure 5B)   (Figure 5D)   (Figure 5F)   (Figure 5H)
  1. Treatment conditions: CFA, n = 17; CFA + MOG35-55, n = 18. Estrous phase: proestrus (n = 4–18/day) or non-proestrus phases (n = 17–30/day). AUC area under the curve.